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The microtubule-associated protein tau is highly soluble under physiological conditions. However, in tauopathies, tau protein aggregates
into insoluble filaments and neurofibrillary tangles (NFTs). The mechanisms underlying the formation of tau filaments and NFTs in
tauopathies remain unclear. Several lines of evidence suggest that transglutaminase may cross-link tau into stable, insoluble aggregates,
leading to the formation of NFTs in Alzheimer’s disease and progressive supranuclear palsy. To further determine the contribution of
transglutaminase in the formation of NFTs, we compared the levels of cross-linked tau protein from P301L tau transgenic mice that
develop NFTs to four-repeat wild-type (4RWT) tau transgenic and nontransgenic mice that do not develop NFT pathology. Immunopre-
cipitation and immunoblotting experiments show that transglutaminase cross-links phosphorylated tau in the hindbrain of P301L tau
transgenic mice but not in mice overexpressing 4RWT tau and nontransgenic mice. Cross-linked, phosphorylated tau from P301L tau
transgenic mice runs as high-molecular mass aggregates on Western blots, similar to cross-linked tau from paired helical filaments of
Alzheimer’s disease. We also used double-label immunofluorescence to demonstrate colocalization of PHF-1-immunoreactive tau and
the transglutaminase-catalyzed cross-link in the hindbrain, spinal cord, and cortex of P301L tau transgenic mice. In the spinal cord, 87%
of PHF-1-labeled cells colocalize with the transglutaminase-catalyzed cross-link. Additionally, transglutaminase enzymatic activity is
significantly elevated in the spinal cord of P301L tau transgenic mice. These studies further implicate transglutaminase in the formation
and/or stabilization of NFT and paired helical filaments and provide a model system to investigate the therapeutic potential of transglu-
taminase inhibitors in tauopathies.
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Introduction
Tauopathies include a clinically diverse group of sporadic and
familial neurodegenerative disorders in which filamentous, in-
traneuronal tau aggregates constitute a hallmark pathological le-
sion. Tau proteins are microtubule-associated proteins that pro-
mote microtubule assembly and confer stability to the
microtubule network (Weingarten et al., 1975; Cleveland et al.,
1977). In tauopathies, abnormally hyperphosphorylated tau po-
lymerizes into straight filaments and paired helical filaments
(PHFs), which aggregate to form neurofibrillary tangles (NFTs).
The progressive accumulation of tau protein in tauopathies such
as Alzheimer’s disease (AD) and progressive supranuclear palsy
(PSP) implicates tau as a factor in neurodegeneration. Although
several potential contributing factors have been identified, the
mechanisms of PHF and NFT formation are not fully
understood.
The insoluble nature of PHFs led to the hypothesis that trans-
glutaminase could contribute to PHF formation in AD (Selkoe et
al., 1982a). Transglutaminases are a family of calcium-dependant
enzymes that catalyze the formation of a covalent -(-glutamyl)
lysine bond between the -carboxamide group of a glutamine
residue and the -amino group of a lysine residue (Folk and Fin-
layson, 1977). Proteins containing the transglutaminase bond
(i.e., cross-link) are highly stable and resistant to proteolysis and
denaturation, similar to the insoluble tau polymers found in
NFTs (Selkoe et al., 1982b). Mounting evidence supports the
involvement of transglutaminase in the pathology of tauopathies.
In vitro studies demonstrate that tau is a substrate of transglu-
taminase (Miller and Anderton, 1986; Dudek and Johnson, 1993;
Miller and Johnson, 1995; Appelt and Balin, 1997; Norlund et al.,
1999). Specifically, two glutamine and 10 lysine residues in tau
are modified by transglutaminase in vitro (Murthy et al., 1998).
Transglutaminase activity (Johnson et al., 1997; Zemaitaitis et al.,
2003) and transglutaminase-catalyzed bonds in PHFs and NFTs
(Balin et al., 1999; Norlund et al., 1999; Zemaitaitis et al., 2000;
Singer et al., 2002) are significantly elevated in brain regions with
abundant neurofibrillary pathology in both AD and PSP. Fur-
thermore, transglutaminase-catalyzed bonds are present in PHF
tau before NFTs are microscopically detectable, implicating
transglutaminase cross-linking of tau protein as an early event in
NFT formation (Singer et al., 2002). However, the role of trans-
glutaminase in the formation of PHFs and NFTs remains unclear.
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The transgenic mice expressing mutant (P301L) tau protein
developed by Lewis et al. (2000) provide an excellent system to
study tau dysfunction. P301L tau mice develop NFTs in the dien-
cephalon, brainstem, cerebellar nuclei, and spinal cord, with
mainly somatodendritic tau immunoreactivity (“pretangles”) ev-
ident in the cortex and hippocampus. Mice overexpressing four-
repeat wild-type (4RWT) tau or nontransgenic animals do not
display NFT pathology. Similar to tauopathies, the accumulation
of NFTs in P301L mice is age dependent (Lewis et al., 2000), with
an increase in tau phosphorylation and insoluble tau (Sahara et
al., 2002). The presence of insoluble tau in the P301L tau trans-
genic mice suggests that transglutaminase could be a factor in
NFT formation in these animals. In this study, we hypothesized
that tau protein from brain and spinal cord tissue of P301L tau
transgenic mice will contain more transglutaminase-catalyzed
cross-links compared with 4RWT tau and nontransgenic mice,
animals that do not exhibit NFT pathology.
Materials and Methods
Antibodies. PHF-1 (kindly provided by Dr. Peter Davies, Albert Einstein
School of Medicine, Bronx, NY) was used at 1:500 for immunoblots and
1:50 for immunohistochemistry. PHF-1 monoclonal antibody (mAb)
recognizes phosphorylated serines 396 and 404 located within the
microtubule-binding repeat on the C terminal of PHF tau protein (Otvos
et al., 1994). AT8 mAb (Pierce, Rockford, IL) recognizes PHF-tau that is
phosphorylated at serine 202 and was used at 1:500 on immunoblots.
Tau-5 mAb (donated by Dr. Lester Binder, Feinberg School of Medicine,
Northwestern University, Chicago, IL) detects an epitope from amino
acids 210 –241 present in all isoforms of tau protein (LoPresti et al., 1995)
and was used at 1:500 for immunoblots. Anti-actin mAb (clone, C4) was
purchased from ICN Biomedicals (Aurora, OH) and used at 1:10,000 on
immunoblots.
Transglutaminase-catalyzed cross-links were detected with mAb 81D4
(CovalAb, Lyon, France) in immunohistochemistry (1:100) and immu-
noprecipitation experiments. The specificity of this antibody has been
demonstrated in numerous publications from our laboratory and others.
Our laboratory has demonstrated previously that 81D4 specifically labels
-(-glutamyl) lysine bonds in tissue sections by performing preadsorp-
tion control experiments with glutamyl-lysine di-peptide containing an
-(-glutamyl) lysine bond (Singer et al., 2002; Zainelli et al., 2003).
Additionally, the 81D4 antibody has been used to quantitate -(-
glutamyl) lysine bonds in AD tissue using a competitive ELISA (Nemes et
al., 2004). This antibody has also been used extensively in immunopre-
cipitation experiments that demonstrate the presence of -(-glutamyl)
lysine cross-links in AD, PSP, and Parkinson’s disease tissue but not in
control tissue (Norlund et al., 1999; Zemaitaitis et al., 2000; Andringa et
al., 2004). The most convincing support for the specificity of the 81D4
antibody for -(-glutamyl) lysine cross-links comes from in vitro and
cell culture experiments. When tau is incubated with transglutaminase in
vitro and subsequently immunoprecipitated with 81D4, it is recognized
on immunoblot by 81D1c2 [another anti--(-glutamyl) lysine bond
antibody] and tau antibody. Tau incubated without transglutaminase
does not react with these anti-cross-link antibodies (Norlund et al.,
1999). Furthermore, huntingtin is immunoprecipitated with 81D4 in
cells cotransfected with truncated, mutant huntingtin protein and trans-
glutaminase but not in cells transfected only with huntingtin (Zainelli et
al., 2003). This result was confirmed by immunoprecipitating huntingtin
and probing immunoblots with 81D1c2.
Animals. P301L tau transgenic mice were from the JNPL3 line previ-
ously described by Lewis et al. (2000). JNPL3 mice were assessed for
presence of motor dysfunction using tests for righting reflex, escape ex-
tension, and rope hang as reported previously (Lewis et al., 2000). For
righting reflex, animals were placed supine and judged for their ability to
right. Unimpaired animals typically right within 1 s. To monitor escape
extension, mice were elevated by their tail, and rear leg extension was
assessed. Unimpaired animals generally place their legs in a wide “V”
away from their bodies. For rope hang, animals were elevated by their
tail, allowed to grasp a horizontal string with both front feet, and then
gently released. Unimpaired animals complete the task by stabilizing
their position with placement of at least one back foot and their tail onto
the string within the 2 min trial. JNPL3 mice used in this study show
dramatic motor dysfunction, including slowed righting reflex and dysto-
nia or scissoring of legs in extension tests. These JNPL3 animals were also
unable to complete the rope-hang task and were unable to initially grasp
the rope for 5 s without falling. JNPL3 mice used for these experiments
were also characterized by reduced ability to freely ambulate, poor
grooming (urine scalding/oily fur), eye irritations, and reduced weight,
which have been shown previously in JNPL3 animals that have motor
impairment (Lewis et al., 2000).
4RWT tau and nontransgenic mice did not exhibit any motor dysfunc-
tion. The age of the animals used in these experiments ranged from 5.5 to
15.5 months, with 4RWT tau and nontransgenic mice age matched to
P301L tau transgenic mice. For immunoblots (except Figs. 1 B, 4 B), the
same 14 mice were used for experiments and loaded on gels in the same
order.
Immunoprecipitation. Hindbrain tissue from P301L tau, 4RWT tau,
and nontransgenic mice was homogenized in three volumes of TBS (10
mM Tris-HCl, pH 7.5, 0.14 M NaCl), 1 mM EDTA, and 1:1000 protease
inhibitor mixture (Sigma, St. Louis, MO). Sarkosyl-insoluble protein
fractions rich in PHF tau protein were prepared from AD temporal cor-
tex (provided by the Loyola University Chicago Brain Bank, Maywood,
IL) following a protocol previously used in our laboratory and others
(Liu et al., 1991; Norlund et al., 1999). Protein concentration was deter-
mined using the BCA Protein Assay kit (Pierce). Immunopurification of
proteins containing -(-glutamyl) lysine bonds was performed using
81D4 mAb prebound to Sepharose beads (CovalAb) according to the
manufacturer protocol and published methods of our laboratory (Nor-
lund et al., 1999; Zemaitaitis et al., 2000). Immunopurified cross-linked
proteins were eluted in 25 l of sample buffer containing 2% SDS at 90°C
and stored at 80°C until Western blot analysis, in which 15 or 25 l was
loaded in each lane.
Immunoblots. Proteins were separated on 10% SDS-polyacrylamide
gels followed by electrophoretic transfer to nitrocellulose membranes.
The proteins examined here are all in the SDS-solubilized fraction. Mem-
branes were then blocked with 0.2% I-Block (Tropix, Bedford, MA) and
0.1% Tween 20 for 1 h at room temperature. Blots were incubated over-
night at 4°C with primary antibodies (described above) diluted in block-
ing solution. The next day, blots were washed with PBS/0.1% Tween 20
and then incubated with anti-mouse secondary antibody conjugated to
HRP (Jackson ImmunoResearch, West Grove, PA) diluted in blocking
solution (1:40,000). Blots were washed and signal was detected using ECL
enhanced chemiluminescence Western blotting detection reagents (Am-
ersham Biosciences, Piscataway, NJ). Immunoblots were quantified by
calculating the integrated optical density (IOD) from the area and optical
density of each protein band on film using Scion Image for Windows
(Scion, Frederick, MD). Film background was measured and subtracted
from each band. Measurements were done in triplicate, and the mean
was calculated. The mean IOD for each band was normalized to actin
(except Fig. 3B).
Double-label fluorescence immunohistochemistry. Fresh-frozen hind-
brain, spinal cord, and cortical tissue was embedded in Tissue-Tek OCT
compound (Sakura Finetek, Torrence, CA). Sixteen-micrometer-thick
sections were mounted on glass slides and fixed with 70% ethanol/0.9%
NaCl for 10 min. Sections were washed with PBS and permeabilized with
PBS/0.2% Triton X-100 for 90 s. After washes with PBS, sections were
blocked with 5% normal goat serum (Vector Laboratories, Burlingame,
CA) in PBS (blocking solution) for 1 h. Sections were then washed with
PBS and incubated overnight in primary antibody (PHF-1; 1:50 in block-
ing solution). The next day, sections were washed with PBS and incu-
bated with goat-anti-mouse secondary antibody (IgG -chain specific;
1:100 in blocking solution) conjugated to fluorescein isothiocyanate
(FITC) (Jackson ImmunoResearch) for 1 h. After washes with PBS, sec-
tions were blocked again, washed with PBS, and incubated overnight
with the second primary antibody (81D4; 1:100 in blocking solution).
After washing sections with PBS, sections were incubated with goat-anti-
mouse secondary antibody (IgM -chain specific; 1:100 in blocking so-
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lution) conjugated to Rhodamine Red-X (Jackson ImmunoResearch) for
1 h. Slides were mounted in Vectashield with 4,6-diamidino-2-
phenylindole (Vector Laboratories) to allow visualization of cell nuclei.
To control for nonspecific labeling of the tissue by secondary antibody,
all experiments included tissue sections in which the primary antibody
was omitted. All steps in this procedure were performed at room
temperature.
The percentage of PHF-1 and 81D4 double labeling was determined in
spinal cord sections from P301L tau, 4RWT, and nontransgenic mice
(n  4 for each group) in two independent experiments. Examination of
the slides blinded to group revealed no specific PHF-1 labeling in 4RWT
tau and nontransgenic animals; therefore, counts were only performed in
P301L tau mice. In each experiment, PHF-1-positive cells and PHF-1 and
81D4 double-labeled cells were counted in three to five random fields
with PHF-1 labeling from three nonserial sections. The percentages of
PHF-1 and 81D4 double-labeled cells were calculated for each animal,
and the means from the two experiments were averaged among the four
P301L tau transgenic mice. Results are expressed as a percentage of PHF-
1-positive cells that colocalize with 81D4 labeling  SEM.
Fluorescence microscopy. Hindbrain and spinal cord sections were
viewed with the 40 objective on an Olympus (Tokyo, Japan) fluores-
cent inverted research microscope configured with Image-Pro Plus 4.5
software (VayTek, Fairfield, IA). Images of optical sections were captured
using a Retiga EX 1350 camera and VolumeScan 3.1 software (VayTek)
with eight-bit/pixel resolution. Three optical sections were deconvolved
using Deconvolution Tools for Windows 9X/NT/2000 software (Vay-
Tek), and a single deconvolved optical section is shown in each figure. All
deconvolved images were obtained using identical parameters. Mono-
chrome images were pseudocolored and merged using Image-Pro Plus 4.5
software. Cortex images were acquired using standard fluorescence micros-
copy (40 objective; camera zoom factor, 2.0) with the merged image gen-
erated by overlaying the red and green images in Image-Pro Plus.
Transglutaminase activity assay. Transglutaminase enzymatic activity
was determined in the spinal cord of P301L tau, 4RWT tau, and non-
transgenic mice by measuring the incorporation of a radioactive poly-
amine donor ( 3H-putrescine) into an exogenous protein acceptor (ca-
sein). Our laboratory has previously published the detailed procedure
used for this assay (Zemaitaitis et al., 2003). Transglutaminase activity
was measured for each animal in two separate assays, and, within an
assay, each sample was measured in triplicate. The assay was repeated five
times to measure samples from five animals in each group. Each sample
contained 100 g of protein. Negative controls for each sample were run
in the absence of calcium and casein. Each assay also included a standard
curve of varying amounts of guinea pig transglutaminase (Sigma). For
each assay, transglutaminase activity for P301L and 4RWT animals was
converted to a percentage control based on the mean value for the non-
transgenic mice. Duplicate measurements for each animal were aver-
aged, and data presented are the group mean  SEM.
Statistics. All statistical analyses were performed using GB-STAT
School Pak (Dynamic Microsystems, Silver Spring, MD). Data are ex-
pressed as means  SEM. For Western blots, a test of homogeneity of
variance revealed unequal variances for some data; thus, a nonparametric
Mann–Whitney U test was used to determine significance ( p  0.05).
Otherwise, data were analyzed using a Student’s t test for separate vari-
ances. Statistical significance was determined in the transglutaminase
activity assay with a one-way ANOVA and Newman–Keuls post hoc test.
Results
Transglutaminase-catalyzed cross-links in phosphorylated
tau protein
To determine whether transglutaminase-catalyzed cross-links
are present in tau protein from P301L tau, 4RWT tau, and non-
transgenic mice, we immunoprecipitated all cross-linked pro-
teins in the hindbrain and detected tau in the pool of cross-linked
proteins by Western blot. The hindbrain was chosen for these
experiments to enrich for brain regions with NFT, including the
pons, medulla, cerebellar nuclei, and brainstem (Lewis et al.,
2000). The age of the animals ranged from 5.5 to 15.5 months,
with all of the P301L tau transgenic animals exhibiting dramatic
motor dysfunction.
Using PHF-1 antibody, which is directed against abnormally
phosphorylated PHF-tau, we detect cross-linked PHF-1-
immunoreactive tau in P301L tau transgenic mice but not in
4RWT tau or nontransgenic mice (Fig. 1A). In some replicates,
high-molecular mass tau bands at 120 kDa are present in P301L
tau lanes (data not shown), suggesting the presence of tau ho-
modimers or cross-linking of tau to other species of similar mo-
lecular mass. Three of the five P301L tau mice showed a smear of
cross-linked, phosphorylated tau protein between 75 and 175
kDa (Fig. 1A). This protein smear is characteristic of aggregated
tau protein in human tauopathies (Norlund et al., 1999; Sergeant
et al., 1999; Zemaitaitis et al., 2000; Zhukareva et al., 2002) and is
demonstrated in Figure 1B, in which we loaded an increased
amount of cross-linked proteins from P30lL animals on gels in
conjunction with cross-linked PHF from the Sarkosyl-insoluble
fraction of AD temporal cortex. Both P301L tau transgenic mice
and AD tissue exhibit a smear of high-molecular mass cross-
linked tau protein, with some cross-linked tau remaining in the
stacking gel (Fig. 1B). The cross-linked proteins were solubilized
in SDS sample buffer before loading on a gel, and therefore the
aggregates we detect are attributable to covalent bonds, such as
the transglutaminase-catalyzed cross-link. The band just above
75 kDa present in all lanes (Fig. 1A) is attributable to nonspecific
binding of secondary antibody, as determined by experiments in
which we omitted the primary antibody (data not shown).
We also used AT8 antibody on Western blots to detect hyper-
phosphorylated tau protein in the immunoprecipitated cross-
linked proteins. Again, hyperphosphorylated cross-linked pro-
tein is present in P301L tau mice but is absent in 4RWT tau and
nontransgenic mice (Fig. 1C). The majority of the cross-linked
tau detected in P301L tau mice with AT8 is monomeric tau run-
ning at 65 kDa. However, this monomeric tau could have been
part of a tau aggregate, because SDS will solubilize some tau
aggregates. A faint smear of cross-linked protein between 75 and
175 kDa is evident in some of the P301L tau mice even after
solubilization with SDS. The band just above 75 kDa present in all
lanes (Fig. 1C) is attributable to nonspecific binding of secondary
antibody, as determined by experiments in which we omitted the
primary antibody (data not shown).
Phosphorylated tau levels
We performed Western blots on SDS-solubilized hindbrain ho-
mogenates to compare the levels of phosphorylated tau among
P301L tau, 4RWT tau, and nontransgenic mice (Fig. 2). Both
P301L tau and 4RWT tau transgenic mice have PHF-1-
immunoreactive tau protein in the hindbrain (Fig. 2A). Two
bands are present in lanes with P301L tau mice hindbrain ho-
mogenates, whereas PHF-1 detects one band in lanes with 4RWT
tau mice hindbrain homogenates. PHF-1 also recognizes two
bands on Western blots prepared with lysates of Chinese hamster
ovary cells transfected with the same tau isoform used in these
transgenic mice (Otvos et al., 1994). Both bands in the P301L tau
lanes were quantified, and the integrated optical densities were
combined for statistical analysis. Phosphorylated tau levels are
not significantly ( p  0.05; Mann–Whitney U test) increased in
P301L tau mice in comparison with 4RWT tau mice (Fig. 2B),
even though PHF-1-immunoreactive tau levels in the P301L tau
mice (4.04  2.20 IOD) are increased twofold over 4RWT mice
(1.73  0.50 IOD). Actin levels show equal protein loading
among lanes (Fig. 2A, bottom panel).
Phosphorylated tau protein was also detected in SDS-
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solubilized hindbrain homogenates from P301L tau and 4RWT
tau transgenic mice with AT8 antibody (Fig. 2C). There was no
significant difference ( p  0.05; Student’s t test) in the level of
AT8-immunoreactive tau between P301L tau (1.02  0.55 IOD)
and 4RWT tau (1.13  0.33 IOD) transgenic mice (Fig. 2D).
Although there is no striking difference in the levels of PHF-1 and
AT-8-positive tau between P301L tau and 4RWT tau transgenic
mice, there is a dramatic qualitative difference in tau species de-
tected with these antibodies. P301L tau transgenic mice clearly
have high-molecular mass tau, whereas the 4RWT tau transgenic
mice do not (Fig. 1).
Transglutaminase-catalyzed cross-links in tau protein
We also used the antibody Tau-5 (that detects all tau species) on
Western blots of the immunoprecipitated cross-linked proteins
to evaluate the amount of tau protein that was cross-linked in the
SDS-solubilized protein fraction (Fig. 3A). The P301L tau trans-
genic animals and 4RWT tau transgenic animals both have cross-
linked tau protein (Fig. 3A). Darker exposures did not reveal
high-molecular mass cross-linked tau protein (data not shown).
Quantification of these data shows that P301L tau transgenic
mice (1.54  0.58 IOD) have 4.5 times more cross-links in tau
compared with 4RWT tau transgenic animals (0.34  0.12 IOD),
and the difference is significant ( p  0.03; Mann–Whitney U
test) (Fig. 3B). Again, we did not detect cross-linked tau protein
in the nontransgenic animals.
Tau protein levels
To determine whether the differences in cross-linked tau between
P301L tau animals and 4RWT animals was a result of unequal
transgene expression, we performed Western blots on SDS-
solubilized hindbrain homogenates and probed for tau with
Tau-5 (Fig. 3C). Quantification and subsequent statistical analy-
sis demonstrated no significant difference between tau protein
levels of P301L (0.63  0.14 IOD) and 4RWT (0.55  0.09 IOD)
tau transgenic mice ( p  0.05; Student’s t test) (Fig. 4E), suggest-
ing that differences in cross-linked tau are not caused by unequal
transgene expression. Tau-5 did not detect the upper band in
P301L tau mice observed with the PHF-1 antibody, although this
might simply reflect the phospho-specific selectivity of the PHF-1
antibody. We reprobed immunoblots with actin (Fig. 3C, bottom
panel) to demonstrate equal protein loading among lanes.
Longer exposures of the blot shown in Figure 3C allow for detec-
tion of endogenous mouse tau with Tau-5 but puts P301L tau and
4RWT tau bands out of a quantifiable range. To show that Tau-5
does recognize endogenous mouse tau in nontransgenic mice, we
ran a separate gel in which we loaded the same amount of protein
from P301L tau and nontransgenic mice as in Figure 3C (10 g)
(Fig. 3D, lanes 1 and 2, respectively), included an additional lane
with 30 g of protein from nontransgenic mice (Fig. 3D, lane 3),
and increased exposure time (Fig. 3D). Thus, the absence of
cross-linked tau in the nontransgenic mice is not a result of an
inability of Tau-5 to detect endogenous mouse tau.
Colocalization of transglutaminase-catalyzed cross-links and
phosphorylated tau
We performed double-label immunofluorescence to determine
whether phosphorylated tau and transglutaminase-catalyzed
cross-links colocalize in the spinal cord, hindbrain, and cortex of
P301L tau, 4RWT tau, and nontransgenic mice. PHF-1 and 81D4
double-labeled cells are present in the spinal cord, hindbrain, and
cortex of P301L tau transgenic mice (Fig. 4). Sections from 4RWT
tau and nontransgenic animals did not have any specific PHF-1
labeling, and therefore no double labeling is present (data not
shown). Cross-link labeling in the 4RWT and nontransgenic
mice is diffuse and without specific cell body labeling. In the
P301L tau transgenic mice, PHF-1 labeling in the cortex is sparse;
Figure 1. Phosphorylated tau is cross-linked in P301L tau transgenic mice. Cross-linked
proteins were immunoprecipitated (IP) with anti-cross-link antibody (81D4) coupled to Sepha-
rose. Phosphorylated tau protein was detected on immunoblot (IB) with PHF-1 (A) and AT8 (C)
antibodies. Transglutaminase-catalyzed cross-links are present in phosphorylated tau (A,
PHF-1; C, AT8) from the hindbrain of P301L tau transgenic mice but not 4RWT tau and nontrans-
genic (nTG) mice. Cross-linked, phosphorylated (PHF-1) tau in P301L mice is similar to cross-
linked tau in PHF from the Sarkosyl-insoluble fraction of AD temporal cortex (B). Note the
phosphorylated tau in the stacking gel (SG) of the lanes with P301L tau mice and AD (B).
Molecular mass in kilodaltons is indicated on the left. Comparable results were obtained in three
independent experiments.
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however, PHF-1 and 81D4 double label-
ing predominates over PHF-1 single label-
ing. Examination of 1908 PHF-1-positive
neurons in the spinal cord of four P301L
tau transgenic mice reveals that 86.95 
0.33% of PHF-1-labeled neurons also la-
bel with the anti-cross-link antibody (Ta-
ble 1).
Transglutaminase activity
Aberrant elevations in transglutaminase
activity have been demonstrated in brain
regions with neurofibrillary pathology in
two human tauopathies (Johnson et al.,
1997; Zemaitaitis et al., 2003). Because the
spinal cord of P301L tau transgenic mice
has been shown previously to develop
abundant NFT (Lewis et al., 2000), we
measured the transglutaminase activity in
the spinal cord of P301L tau, 4RWT tau,
and nontransgenic mice. The activity of
guinea pig liver transglutaminase was
measured in each assay in range from 0.01
to 0.1 g and resulted in linear correlation
values from 0.999 to 0.96. The activity of
transglutaminase in the spinal cord sam-
ples fell within this linear range for guinea
pig liver transglutaminase. Our data reveal
a significant (F(2,12)  11.5; p  0.0016)
increase in the transglutaminase activity in
the spinal cord of P301L tau mice (384 
80% control) compared with 4RWT tau
(91.8  27.4% control) and nontransgenic mice (100  10.1%
control) (Fig. 5). There was no significant difference in transglu-
taminase activity in 4RWT tau mice compared with nontrans-
genic mice.
Discussion
Transglutaminase is an enzyme that cross-links proteins, render-
ing them stable and insoluble. The insoluble tau protein in P301L
tau transgenic mice (Lewis et al., 2000; Sahara et al., 2002)
prompted us to investigate the potential involvement of transglu-
taminase in the neurofibrillary pathology of these mice. The re-
sults presented here demonstrate that transglutaminase cross-
links tau protein in P301L tau mice, an animal model previously
shown to develop NFT (Lewis et al., 2000).
Immunoprecipitation experiments revealed that transglu-
taminase cross-links are present in phosphorylated tau (detected
with PHF-1 and AT8) from P301L tau transgenic mice but not
4RWT and nontransgenic mice (Fig. 1). We also detected high-
molecular mass aggregates of cross-linked, phosphorylated tau
protein between 75 and 175 kDa in P301L tau mice (Fig. 1A,C).
When we loaded an increased amount of cross-linked proteins on
Western blot, cross-linked, phosphorylated tau protein was de-
tected in P301L tau mice above 175 kDa and also in the stacking
gel (Fig. 1B). This high-molecular mass tau is consistent with
intermolecular cross-links producing tau aggregates. Similarly,
cross-linked PHF-tau protein appeared as a smear on Western
blots in both AD (Fig. 1B) (Norlund et al., 1999) and PSP (Zem-
aitaitis et al., 2000). It is important to note that these intermolec-
ular cross-links could arise via several different scenarios. Trans-
glutaminase may form cross-links among several tau proteins or
cross-link tau to one or more other proteins found in NFT. Al-
ternatively, transglutaminase may cross-link ubiquitinated tau
via the ubiquitin moiety. Tau is ubiquitinated in AD
(Morishima-Kawashima et al., 1993), and tau filaments in P301L
tau mice are ubiquitin positive (Lin et al., 2003). Recent evidence
suggests that transglutaminase cross-links ubiquitin and heat
shock protein 27 in tau-positive polymers isolated from AD brain
(Nemes et al., 2004).
Most of the cross-linked tau in P301L tau transgenic animals
ran at 65 kDa on Western blots, suggesting intramolecular
cross-links in monomeric tau or incorporation of a small poly-
amine (Figs. 1A,C, 3A). Polyamidated tau displays increased sta-
bility (Tucholski et al., 1999); however, this does not necessarily
translate into tau aggregation. 4RWT tau transgenic mice have
monomeric tau with intramolecular cross-links or incorporation
of a small polyamine (Fig. 3A) but do not develop tau aggregates
(Figs. 1, 3A) or NFT (Lewis et al., 2000). 4RWT animals have
significantly lower levels of cross-linked, monomeric tau protein
detected with Tau-5 (Fig. 3A,B), and these levels may not pro-
duce enough stable tau to result in aggregate formation.
Cross-linked, phosphorylated tau was not present in 4RWT or
nontransgenic animals (Fig. 1A,C), animals that do not develop
NFT. However, 4RWT tau transgenic mice do have tau protein
phosphorylated at the PHF-1 and AT8 sites (Fig. 2A,C). Either
transglutaminase does not cross-link phosphorylated tau in the
4RWT mice or the levels are below the limits of detection. Over-
expression of 4RWT tau in mice is sufficient to cause cross-
linking of tau (Fig. 3A) but not cross-linking of phosphorylated
tau (Fig. 1A,C). The unique aspect of the P301L tau mice was the
presence of cross-linked PHF-1-labeled tau that ran at molecular
masses consistent with tau aggregation. These data are consistent
Figure 2. Phosphorylated tau levels in P301L tau, 4RWT tau, and nontransgenic (nTG) mice. Phosphorylated tau in hindbrain
homogenates was detected with PHF-1 (A) and AT8 (C) antibodies. Molecular mass in kilodaltons is indicated on the left. The
immunoblots (IB) were reprobed with an antibody against actin (A, C, bottom panels) to demonstrate equal protein loading
among lanes. The levels of phosphorylated tau in the P301L tau animals were not significantly different from 4RWT tau mice for
both PHF-1 (B; p  0.05; Mann–Whitney U test) and AT8 (D; p  0.05; Student’s t test) antibodies. The IODs of both bands in the
P301L tau mice lanes were included in the PHF-1 data analysis. All data were normalized to actin. Data shown are mean IODSEM
and are representative of three experiments.
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with the hypothesis that cross-linking of phosphorylated tau is
dependent on initial tau aggregation.
In P301L tau mice, phosphorylated tau and the
transglutaminase-catalyzed bond colocalized in the hindbrain
and spinal cord, regions previously shown to develop NFT, and
cortex, a region with pretangle pathology (Fig. 4) (Lewis et al.,
2000). Both neurons and oligodendrocytes of P301L tau mice
contain tau filaments (Lin et al., 2003), and therefore the PHF-1
and cross-link colocalization detected here could arise from ei-
ther cell type. Quantification of double labeling in the spinal cord
of P301L mice indicated that 87% of PHF-1-positive cells also
labeled with an anti-cross-link antibody (Table 1). Approxi-
mately 13% of PHF-1-positive cells in the spinal cord of P301L
tau mice were not double labeled with the cross-link antibody.
PHF assembly appears to occur in stages (Friedhoff et al., 1998),
and this noncross-linked, phosphorylated tau protein may rep-
resent a stage of PHF formation in which tau aggregates are un-
stable. When anionic inducing agents stimulate PHF formation
in vitro, the stability of the tau aggregates and resistance to dena-
turation is low (Li et al., 2002). However, combining transglu-
taminase with tau in vitro results in stable, insoluble tau filaments
(Dudek and Johnson, 1993; Appelt and Balin, 1997) that are bio-
chemically similar to PHF from AD (Selkoe et al., 1982a). To-
gether, these data suggest that the formation of PHF and the
stabilization of PHF by transglutaminase in tauopathies can oc-
cur independently. The transglutaminase cross-linking of tau
protein present in transgenic mice and human disease with neu-
rofibrillary pathology may be necessary
for the stabilization of PHF in vivo.
Lysine residues involved in
transglutaminase-catalyzed cross-links
are located adjacent to the microtubule-
binding repeats in tau protein (Murthy et
al., 1998), which form the core of PHF in
AD (Crowther et al., 1989). Conceivably,
transglutaminase would not have access to
these sites while tau is bound to microtu-
bules. An elevation in unbound tau could
contribute to the cross-linking of tau ob-
served in the P301L tau transgenic mice
(Fig. 1). In vitro, recombinant P301L tau
protein displays a reduced ability to bind
to microtubules (Hong et al., 1998; De-
Ture et al., 2000). Tau mutations seem to
have an inconsistent effect on tau-
microtubule interactions in cell culture
(Dayanandan et al., 1999; DeTure et al.,
2000; Perez et al., 2000; Lu and Kosik,
2001; Nagiec et al., 2001), but the impact
of mutant tau on microtubule interactions
may not be immediate and thus not ap-
parent in transient expression systems.
Additionally, tau in these systems has not
been reported to form aggregates. How-
ever, in cells that stably express mutant tau
at levels that saturate microtubules and el-
evate free cytoplasmic tau, mutant tau, but
not wild-type tau, forms filaments (De-
Ture et al., 2002). Presumably abnormal,
unbound tau in P301L mice eventually
achieves high-enough levels to result in
initial tau aggregation. Work by Zhang et
al. (2004) supports this theory by showing
that mutant tau (R406W) expressed in transgenic mice displays a
reduced ability to bind microtubules compared with wild-type
tau expressed in transgenic mice.
Calcium positively regulates transglutaminase activity (Folk
and Finlayson, 1977). Dysregulation of calcium homeostasis is
hypothesized to exert a pathological role in AD (LaFerla, 2002)
and could underlie the increase in transglutaminase activity mea-
sured in AD (Johnson et al., 1997). We found a significant in-
crease in transglutaminase activity in P301L tau mice compared
with 4RWT tau and nontransgenic mice (Fig. 5). Furukawa et al.
(2000, 2003) demonstrated in cell culture that mutant tau
(V337M) causes elevations in intracellular calcium. An increase
in intracellular calcium precipitated by mutant tau could elicit
the elevation in transglutaminase activity in P301L tau mice, re-
sulting in pathological cross-linking of tau protein.
Aberrant transglutaminase activity has been implicated in
PHF/NFT formation in AD and PSP (Kim et al., 2002). The basis
for this hypothesis and supporting data is the result of primarily
human postmortem and in vitro studies. Although these types of
studies provide extremely valuable insight into disease processes,
they cannot always lend insight into the progressive nature of
disease mechanisms. P301L tau transgenic mice develop NFTs
and have cross-linked tau protein; thus, they can be used to ex-
amine cross-linking of tau protein during disease progression
and determine whether transglutaminase plays an early role in
PHF/NFT formation. P301L tau transgenic mice can further be
used to appreciate the impact of transglutaminase inhibition on
Figure 3. Tau protein is cross-linked in P301L and 4RWT tau transgenic mice. Cross-linked proteins in the hindbrain of P301L
tau, 4RWT tau, and nontransgenic (nTG) mice were immunoprecipitated (IP) with anti-cross-link antibody (81D4) coupled to
Sepharose, and tau protein was detected on immunoblot (IB) with Tau-5 antibody (A). The levels of cross-linked tau in the P301L
tau animals were significantly higher than 4RWT tau mice (B; *p  0.03; Mann–Whitney U test). Tau protein levels in the
hindbrain of P301L tau, 4RWT tau, and nontransgenic mice were detected with Tau-5 antibody (C). Actin levels (C, bottom panel)
confirmed equal protein loading. To show that Tau-5 antibody recognizes endogenous mouse tau, the same amount of protein
from hindbrain homogenates of P301L tau and nontransgenic mice as in C (10 g of protein; lanes 1 and 2, respectively) was
loaded along with 30 g of protein from nontransgenic mice (lane 3) (D). The darker exposure shown here (compared with C)
allows for detection of endogenous mouse tau with Tau-5. The levels of tau (normalized to actin) in the P301L tau animals were not
significantly higher than those in 4RWT tau mice (E; p  0.05; Student’s t test). Molecular mass in kilodaltons is indicated on the
left. Data shown are mean IODs  SEM and are representative of three experiments.
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PHF/NFT formation and phenotypic manifestations of the ani-
mal model. Similar experiments have been executed to illuminate
the importance of transglutaminase in the pathology of Hunting-
ton’s disease, in which intranuclear huntingtin aggregates have
been shown to contain transglutaminase-catalyzed cross-links
(Zainelli et al., 2003). Two separate studies treated a transgenic
mouse model of Huntington’s disease with cystamine, an inhib-
itor of transglutaminase. Results indicate that cystamine inhib-
ited transglutaminase activity, prolonged survival, improved mo-
tor performance (Dedeoglu et al., 2002; Karpuj et al., 2002) and,
if administered before the onset of motor disturbances, decreased
the amount of huntingtin-positive inclusions (Dedeoglu et al.,
2002). It should be noted that cystamine may have other benefi-
cial effects in addition to inhibiting transglutaminase. However,
strategies aimed at specifically inhibiting transglutaminase may
offer therapeutic potential in neurodegenerative diseases with
protein aggregation as a pathological hallmark.
The data presented here demonstrate that phosphorylated,
high-molecular mass tau protein is cross-linked and transglu-
taminase activity is elevated in transgenic mice that develop NFT.
The electrophoretic pattern of cross-linked, phosphorylated tau
strongly resembles that of PHF from AD and PSP. Furthermore,
phosphorylated tau and the transglutaminase-catalyzed cross-
link are highly colocalized in P301L tau transgenic mice. Mice
that do not develop NFT do not have high-molecular mass ag-
gregated tau protein or colocalization of phosphorylated tau and
the transglutaminase bond. These results support the hypothesis
that transglutaminase-catalyzed cross-linking of phosphorylated
tau protein is involved in NFT formation and/or stabilization in
human tauopathies, such as AD and PSP. P301L tau transgenic
mice provide an excellent model to further study the role of trans-
glutaminase in tau aggregation and neurofibrillary pathology.
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